慢性淋巴细胞白血病T细胞中的免疫功能障碍以及来那度胺作为一种免疫调节药物
Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug.
作者信息
Ramsay Alan G, Gribben John G
出版信息
Haematologica. 2009 Sep;94(9):1198-202. doi: 10.3324/haematol.2009.009274.
Abstract
A new agent that is being used in chronic lymphocytic leukemia (CLL) and is receiving considerable interest is the immunomodulatory drug lenalidomide. The precise anti-CLL mechanism of action of lenalidomide is not yet completely defined. In this perspective article, Drs. Ramsay and Gribben examine the multiple biological effects of lenalidomide on various cell targets that likely contribute to its anti-CLL activity. See related paper on page 1266.
摘要
一种正在慢性淋巴细胞白血病（CLL）治疗中使用且备受关注的新型药物是免疫调节药物来那度胺。来那度胺确切的抗CLL作用机制尚未完全明确。在这篇观点文章中，拉姆齐博士和格里本博士探讨了来那度胺对多种细胞靶点的多重生物学效应，这些效应可能有助于其抗CLL活性。见第1266页的相关论文。
相似文献
1
Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug.慢性淋巴细胞白血病T细胞中的免疫功能障碍以及来那度胺作为一种免疫调节药物
Haematologica. 2009 Sep;94(9):1198-202. doi: 10.3324/haematol.2009.009274.
2
Lenalidomide alone and in combination for chronic lymphocytic leukemia.来那度胺单药及联合治疗慢性淋巴细胞白血病。
Curr Hematol Malig Rep. 2013 Mar;8(1):7-13. doi: 10.1007/s11899-012-0146-x.
3
Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong?免疫调节剂在慢性淋巴细胞白血病中的应用：来那度胺属于哪一类？
Leuk Lymphoma. 2010 Aug;51(8):1382-5. doi: 10.3109/10428194.2010.496017.
4
Lenalidomide in the treatment of chronic lymphocytic leukemia.来那度胺治疗慢性淋巴细胞白血病
Expert Opin Investig Drugs. 2017 May;26(5):633-650. doi: 10.1080/13543784.2017.1313230. Epub 2017 Apr 17.
5
Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia.来那度胺治疗可调节慢性淋巴细胞白血病患者的 T 细胞免疫表型和细胞因子产生。
Cancer. 2011 Sep 1;117(17):3999-4008. doi: 10.1002/cncr.25983. Epub 2011 Feb 24.
6
Immunomodulatory drugs in chronic lymphocytic leukemia: a new treatment paradigm.慢性淋巴细胞白血病中的免疫调节药物：一种新的治疗模式。
Leuk Lymphoma. 2007 May;48(5):866-9. doi: 10.1080/10428190601126636.
7
Lenalidomide in the treatment of chronic lymphocytic leukemia.来那度胺治疗慢性淋巴细胞白血病。
Expert Opin Investig Drugs. 2011 Feb;20(2):273-86. doi: 10.1517/13543784.2011.546343. Epub 2011 Jan 10.
8
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.来那度胺治疗复发或难治性慢性淋巴细胞白血病患者的临床疗效：一项II期研究结果
J Clin Oncol. 2006 Dec 1;24(34):5343-9. doi: 10.1200/JCO.2005.05.0401. Epub 2006 Nov 6.
9
Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.多种抑制性配体诱导慢性淋巴细胞白血病 T 细胞免疫突触功能障碍，来那度胺可阻断该功能：在人类癌症中建立一种可逆的免疫逃逸机制。
Blood. 2012 Aug 16;120(7):1412-21. doi: 10.1182/blood-2012-02-411678. Epub 2012 Apr 30.
10
Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia.来那度胺治疗复发性慢性淋巴细胞白血病的长期分子缓解。
Eur J Haematol. 2013 Apr;90(4):340-4. doi: 10.1111/ejh.12068. Epub 2013 Feb 14.
引用本文的文献
1
CCL2 mediated IKZF1 expression promotes M2 polarization of glioma-associated macrophages through CD84-SHP2 pathway.CCL2 介导的 IKZF1 表达通过 CD84-SHP2 通路促进胶质瘤相关巨噬细胞的 M2 极化。
Oncogene. 2024 Aug;43(36):2737-2749. doi: 10.1038/s41388-024-03118-w. Epub 2024 Aug 7.
2
Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2.维奈托克通过靶向BCL2克服急性髓系白血病中的索拉非尼耐药性。
Biology (Basel). 2023 Oct 16;12(10):1337. doi: 10.3390/biology12101337.
3
Targeting the tumor microenvironment in chronic lymphocytic leukemia.靶向慢性淋巴细胞白血病中的肿瘤微环境。
Haematologica. 2021 Sep 1;106(9):2312-2324. doi: 10.3324/haematol.2020.268037.
4
T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective.从表观遗传学角度探讨慢性淋巴细胞白血病中的 T 细胞功能障碍。
Haematologica. 2021 May 1;106(5):1234-1243. doi: 10.3324/haematol.2020.267914.
5
Novel Therapy Approaches to Follicular Lymphoma.滤泡性淋巴瘤的新型治疗方法。
Drugs. 2021 Mar;81(4):453-469. doi: 10.1007/s40265-020-01446-1.
6
IL-21 modulates memory and exhaustion phenotype of T-cells in a fatty acid oxidation-dependent manner.白细胞介素-21以脂肪酸氧化依赖的方式调节T细胞的记忆和耗竭表型。
Oncotarget. 2018 Feb 7;9(17):13125-13138. doi: 10.18632/oncotarget.24442. eCollection 2018 Mar 2.
7
Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).布鲁顿酪氨酸激酶抑制剂：用于慢性淋巴细胞白血病（CLL）患者的第一代和第二代药物。
Expert Opin Investig Drugs. 2018 Jan;27(1):31-42. doi: 10.1080/13543784.2018.1404027. Epub 2017 Nov 15.
8
Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma.来那度胺增强 CS1 嵌合抗原受体修饰 T 细胞对多发性骨髓瘤的功能。
Clin Cancer Res. 2018 Jan 1;24(1):106-119. doi: 10.1158/1078-0432.CCR-17-0344. Epub 2017 Oct 23.
9
Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells.来那度胺诱导T细胞产生白细胞介素-21并增强IL21介导的慢性淋巴细胞白血病B细胞的细胞毒性。
Cancer Immunol Res. 2016 Aug;4(8):698-707. doi: 10.1158/2326-6066.CIR-15-0291. Epub 2016 Jun 10.
10
Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.苯达莫司汀+利妥昔单抗化学免疫疗法及来那度胺维持治疗复发难治性慢性淋巴细胞白血病和小淋巴细胞淋巴瘤：威斯康星肿瘤学网络研究
Br J Haematol. 2016 Apr;173(2):283-91. doi: 10.1111/bjh.13957. Epub 2016 Feb 23.
本文引用的文献
1
Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.来那度胺诱导肿瘤细胞上CD80上调与T细胞活化、细胞因子释放综合征的快速发作以及慢性淋巴细胞白血病中白血病细胞清除相关。
Haematologica. 2009 Sep;94(9):1266-73. doi: 10.3324/haematol.2009.005835.
2
E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction.E(μ)-TCL1小鼠代表了一种用于慢性淋巴细胞白血病诱导的T细胞功能障碍免疫治疗逆转的模型。
Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6250-5. doi: 10.1073/pnas.0901166106. Epub 2009 Mar 30.
3
The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia.人源化CD40抗体SGN-40在慢性淋巴细胞白血病中表现出临床前活性，来那度胺可增强该活性。
Br J Haematol. 2009 Mar;144(6):848-55. doi: 10.1111/j.1365-2141.2008.07548.x. Epub 2009 Jan 12.
4
Stem cell transplantation in chronic lymphocytic leukemia.慢性淋巴细胞白血病中的干细胞移植
Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):53-8. doi: 10.1016/j.bbmt.2008.10.022.
5
Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia.来那度胺相关的肿瘤细胞因子释放反应在慢性淋巴细胞白血病患者中是可控的。
J Clin Oncol. 2008 Oct 10;26(29):4851-2; author reply 4852-3. doi: 10.1200/JCO.2008.18.2857. Epub 2008 Sep 8.
6
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.来那度胺下调CD20抗原，并拮抗利妥昔单抗对原发性慢性淋巴细胞白血病细胞的直接细胞毒性和抗体依赖性细胞毒性。
Blood. 2008 Dec 15;112(13):5180-9. doi: 10.1182/blood-2008-01-133108. Epub 2008 Sep 4.
7
lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.来那度胺增强利妥昔单抗治疗的CD20+肿瘤细胞的自然杀伤细胞和单核细胞介导的抗体依赖性细胞毒性。
Clin Cancer Res. 2008 Jul 15;14(14):4650-7. doi: 10.1158/1078-0432.CCR-07-4405.
8
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.慢性淋巴细胞白血病T细胞表现出免疫突触形成受损，而这可以通过一种免疫调节药物逆转。
J Clin Invest. 2008 Jul;118(7):2427-37. doi: 10.1172/JCI35017.
9
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.更高剂量的来那度胺与不可接受的毒性相关，包括慢性淋巴细胞白血病患者出现危及生命的肿瘤细胞因子释放。
J Clin Oncol. 2008 May 20;26(15):2519-25. doi: 10.1200/JCO.2007.13.9709. Epub 2008 Apr 21.
10
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.氟达拉滨、环磷酰胺和利妥昔单抗方案作为慢性淋巴细胞白血病初始治疗的长期结果
Blood. 2008 Aug 15;112(4):975-80. doi: 10.1182/blood-2008-02-140582. Epub 2008 Apr 14.
Zotero 插件